Therapy Areas: Oncology
CSI Laboratories Partners with Dr. Maher Albitar of Genomics Testing Cooperative
7 December 2018 - - US-based cancer diagnostics company CSI Laboratories has forged partnership with US-based molecular testing firm Genomic Testing Cooperative in order to provide a new level of Next Generation Sequencing to the market, the company said.

This partnership combines the gold standard in quality cancer diagnostics with advanced genomics technology - giving pathologists and oncologists access to the most comprehensive and detailed cancer data. This information also enables physicians to gauge prognosis and recommend more personalized patient treatments as needed.

The partnership's focus on quality and technology has already made CSI Laboratories the first in the market to offer 177 gene panel liquid biopsy for hematology accelerating cancer diagnostic speed and accuracy.

The combined menu of CSI Laboratories and GTC tests represents the most comprehensive and innovative offering in cancer patient profiling on the market.

Dr. Maher Albitar, founder of GTC and former senior vice president, Chief Medical officer, and director of R and D at NeoGenomics Laboratories, will be hosting a webinar alongside CSI Laboratories' medical director, Dr. Lawrence Hertzberg, M.D., to discuss the partnership's goals and forthcoming capabilities regarding cancer diagnostics.

CSI Laboratories' clients benefit from having access to an experienced medical team, highly trained technologists and expert scientific advisors dedicated to ensuring the details of every test result are understood in order to personalize patient treatment plans.

The company is a specialised cancer diagnostics laboratory focused specifically on meeting the unique needs and challenges of pathologists and community hospitals.

Genomic Testing Cooperative is a privately-owned molecular testing company located in Irvine, CA.

The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing. 

Molecular alterations are identified based on rigorous testing with the aid of specially developed algorithms to increase accuracy and efficiency. The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead.